<DOC>
	<DOCNO>NCT01934335</DOCNO>
	<brief_summary>The purpose research study test whether vandetanib effect tumor growth marker . Vandetanib approve FDA use treat breast cancer . This study compare vandetanib placebo . The propose study design determine change Ki-67 expression pair breast cancer sample obtain treatment vandetanib . Other tumor marker include RET , TUNEL phosphorylation specific level ERK1/2 , AKT mTOR also assess paired sample . Subjects core biopsy breast demonstrate invasive breast cancer require surgical excision lesion eligible inclusion study . The tyrosine kinase inhibitor , vandetanib 300 mg , give day 7-14 day prior surgery . Following surgery , tissue marker would analyze paired sample , allow rapid assessment vivo response TKI treatment .</brief_summary>
	<brief_title>Effect Vandetanib Cellular Markers Invasive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients core breast biopsy , pathology review , demonstrate invasive breast cancer determine need surgical excision lesion . All subtypes invasive breast cancer enrol . Core biopsy specimen enrol patient stain RET immunohistochemistry score , however , patient exclude accord RET expression . Female gender Age &gt; /= 18 year age ECOG performance status &lt; /= 2 Life expectancy great 6 month Ability willingness provide inform consent participate study Prolonged QT interval ( QTc &gt; 480 millisecond ) screen EKG congenital long QT syndrome Any concomitant medication know associated Torsades de Pointes QT elongation ( see appendix 2 ) . Hypertension control medical therapy ( systolic BP great 160 millimeter mercury [ mmHg ] diastolic blood pressure great 100 mmHg ) . Patients take metformin digoxin . History arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia ) , symptomatic require treatment ( CTCAE Grade 3 ) , symptomatic uncontrolled atrial fibrillation despite treatment , asymptomatic sustain ventricular tachycardia . Patients atrial fibrillation control medication permit . Significant cardiac event ( e.g. , myocardial infarction ) , superior vena cava syndrome , New York Heart Association ( NYHA ) classification heart disease â‰¥2 within 12 week , presence cardiac disease opinion Investigator increase risk ventricular arrhythmia . Serum calcium magnesium outside institutional range normal . Serum Potassium &lt; 4.0 mmol/L 5.0 mmol/L Creatinine clearance &lt; 50 ml/min PT &gt; 12 second PTT &gt; 31 second Platelet count &lt; 100,000 Serum bilirubin great 1.5 mg/dl Alanine aminotransferase ( ALT ) &gt; 50 U/L , aspartate aminotransferase ( AST ) &gt; 65 U/L , alkaline phosphatase ( ALP ) &gt; 250 U/L Any cytotoxic treatment , neoadjuvant chemotherapy , plan subsequent surgical procedure . Previous exposure Vandetanib Previous enrollment randomization study Involvement planning and/or conduct study ( applies AstraZeneca staff staff UIHC ) . Previous current malignancy histology within last 5 year , exception situ carcinoma cervix , adequately treat basal cell squamous cell carcinoma skin . Patients receive prior surgical site radiation . Patients CYP3A4 inhibitor inducer ( see appendix 1 ) . Inability test core biopsy study marker Pregnancy lactation time study entry . ( Note : Pregnancy test must perform within 2 week prior randomization accord institutional standard woman childbearing potential . )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>breast cancer , TKI , tyrosine kinase inhibitor , vandetanib , Ki-67</keyword>
</DOC>